

Prescription Drug Affordability Board Meeting

July 11, 2025

July 11 Meeting Agenda

Call to Order, Roll Call, Minutes Approval

10:00 - 10:05 am

Board Member & Director Updates

10:05 - 10:10 am

Board Business

10:10 - 11:10 am

The Board may meet in Executive Session to receive legal advice regarding use of data by the Board in setting an upper payment limit, pending litigation, section 24-4-105, C.R.S., and section 24-4-103(4)(a), C.R.S., pursuant to section 24-6-402(3)(a)(II), C.R.S.

Public Comment

10:10 - 11:30 am

Comments will be limited to 2 minutes per person or organization.

Break

11:30 - 11:40 am

Rulemaking Hearing

11:40 am - 1:00 pm

Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3. Upper Payment Limit for Enbrel/Etanercept

- Rule Introduction
- Witness Testimony

Witness testimony will be limited to three minutes per person. The Board may ask questions to the person testifying regarding their testimony. The time limit will not count towards answering any of the Board's questions. We will try to get to every testimony during the rulemaking hearing. However, if you are not selected to speak due to time constraints, please submit written testimony and sign up to testify at the next rulemaking hearing.

- Board Deliberation

The Board may meet in Executive Session to discuss confidential, trade-secret, or proprietary information pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3), C.R.S.

If you are in need of an accommodation to access PDAB meetings or materials, please notify staff at dora_ins_pdab@state.co.us.

Councilmembers of the Prescription Drug Affordability Advisory Council may attend the July 11, 2025, Prescription Drug Affordability Board Meeting and may participate in the meeting, which may include providing public comment.

Call to Order Roll Call Minutes Approval

May 23 Meeting Minutes

Board Member Updates & Director Updates



The Prescription Drug Affordability Board is in Executive Session

*The Board may meet in Executive Session to receive legal advice regarding use of data by the Board in setting an upper payment limit, pending litigation, **section 24-4-105, C.R.S., and section 24-4-103(4)(a), C.R.S.,** pursuant to section 24-6-402(3)(a)(II), C.R.S.*

Public Comment

- *Comments will be limited to 2 minutes per person or organization.*
- *Please sign up via the link in the chat.*
- *Please limit comments regarding an Enbrel UPL to the rulemaking hearing portion of the meeting.*
- *Please keep your comments civil. Personal attacks against Board members, Division staff, stakeholders, or other individuals will not be recognized.*


Break

The meeting will resume after a 10-minute break.

Rulemaking Hearing

*Prescription Drug Affordability Board Rule 3 CCR 702-9:
Part 4.3 Upper Payment Limit for Enbrel (Etanercept)*

Rulemaking Hearing Overview



UPL Rulemaking Hearing


Director Presentation - Descriptions of Rule



Board Director, Sophie Thomas, will provide descriptions of the *Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel*.

UPL Rulemaking Hearing

Providing Testimony During Today's Rulemaking Hearing



Reminders

- The purpose of the rulemaking hearing is for Board members to gather information about proposed amendments to the affordability review rule, rather than discuss previous Board deliberations and actions.
- Testimony is a time to provide feedback on the affordability review rule only. Stakeholders are asked to reserve other comments for the public comment period of the meeting.

UPL Rulemaking Hearing

Board Deliberation & Vote - Continue the UPL Rulemaking Hearing



Board Action Item

Board deliberates

Board may vote to:

- Continue the UPL rulemaking hearing on Part 4.3 at its next meeting on August 22, 2025, to allow additional stakeholder input and Board deliberation.

Upcoming Meetings

PDAB Meeting: August 22 at 10 am MT

PDAAC Meeting: August 28 at 9 am MT

For meeting minutes, agendas, and general information about PDAB, visit <https://doi.colorado.gov/insurance-products/health-insurance/prescription-drug-affordability-review-board>

Questions about the Prescription Drug Affordability Board and Advisory Council can be sent to dora_ins_pdab@state.co.us.

If you are in need of an accommodation to access PDAB meetings or materials, please notify staff at dora_ins_pdab@state.co.us.



The Prescription Drug Affordability Board is in Executive Session

*The Board may meet in Executive Session to receive legal
advice pursuant to section 24-6-402(3)(a)(II), C.R.S.*



The Prescription Drug Affordability Board is in Executive Session

The Board may also meet in Executive Session to discuss confidential, trade-secret, or proprietary information pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3), C.R.S.



The Prescription Drug Affordability Board is in Executive Session

The Board may also meet in Executive Session to discuss confidential, trade-secret, or proprietary information regarding Enbrel's WAC and net price, pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3), C.R.S.